<h4>Purpose</h4>Standard neoadjuvant therapy for early HER2-positive breast cancer consists of 18 weeks of carboplatin, docetaxel, trastuzumab, and pertuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.